Item 2.02 Results of Operations and Financial Condition.
On
A copy of the Letter is furnished herewith as Exhibit 99.1 and is incorporated
herein by reference. The information in this Item 2.02, and in Exhibit 99.1
hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information contained in this report and in the accompanying
exhibit shall not be incorporated by reference into any filing with the
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On
--------------------------------------------------------------------------------
Item 7.01 Regulation FD Disclosure.
The information set forth in Item 2.02 above is incorporated by reference here.
Statements in this filing, including Exhibit 99.1 hereof, regarding future
events, results or expectations are forward-looking statements that involve
risks and uncertainties. Forward-looking statements include, but are not limited
to, expectations regarding the expected actions and timing for winding down and
terminating existing studies, timing and expectations regarding future
interactions with the FDA, estimated 2019 year-end cash and estimated cash burn
in the first half of 2020. Actual results may differ from these expectations as
a result of a number of factors, including expected cash is preliminary, and
subject to adjustment during the audit process, and those set forth under the
caption "Risk Factors" in CymaBay's Quarterly Report on Form 10-Q for the
quarter ended
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description 99.1 Letter to Stockholders 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source